期刊文献+

阿卡波糖对老年糖耐量减低患者颈动脉内中膜厚度的影响 被引量:1

The Effect of Acarbose on Carotid Intimamedia Thickness in the Elderly Patients with Impaired Glucose Tolerance
原文传递
导出
摘要 目的观察阿卡波糖对老年糖耐量减低患者颈动脉内中膜厚度的影响。方法120例老年糖耐量减低患者分为两组:60例口服阿卡波糖50 mg,3次.d-1,持续1年,60例未服药,均随访1年。结果治疗后4周患者口服馒头餐后2 h血糖明显下降(P<0.01);1年后治疗组患者HbA1 c明显减低(P<0.05),平均颈动脉内中膜厚度增加治疗组明显低于对照组(P<0.05)。结论阿卡波糖有效降低糖耐量减低患者餐后血糖,长期治疗可降低糖化血红蛋白,减缓动脉粥样硬化的发展。 OBJECTIVE To observe the effect of acarbose on carotid intimamedia thickness (IMT) in the elderly patients with impaired glucose tolerance (IGT). METHODS 120 cases of elderly patients with IGT were divided into two groups: 60 cases of oral Acarbose 50 mg, 3 times per day, continued one year,60 cases of no medication,all patients were followed up for 1 year. RESULTS Plasma glucose after steamed bread meal 2 hours (2hPG) was lowered obviously by treated for 4 weeks (P 〈 0.01 ). After 1 year HbAlc was reduced (P 〈 0.05). The average IMT increased in the treatment group was significantly lower than that of control group (P 〈 0.05). CONCLUSION Acarbose reduced 2hPG in the elderly patients with IGT , long-term treatment can reduce HbAI c and delay the development of arteriosclerosis.
出处 《中国现代应用药学》 CAS CSCD 北大核心 2009年第1期72-74,共3页 Chinese Journal of Modern Applied Pharmacy
关键词 阿卡波糖 颈动脉内中膜厚度 糖耐量减低 acarbose carotid IMT IGT
  • 相关文献

参考文献10

  • 1张翼飞,洪洁,顾卫琼,孙首悦,唐金凤,江凌,戴蒙,赵咏桔,宁光.血清游离脂肪酸水平在不同体重指数及糖耐量个体中与胰岛素敏感性及相关指标的关系[J].中华内科杂志,2003,42(11):793-796. 被引量:16
  • 2De VEGT F,DEKKER J M, RUHE H G, et al. Hyperglycemia is associated with all-cause and cardiovascular mortality in the Hoorn population : the Hoorn Study [ J ] . Diabetologia, 1999,42 ( 8 ) : 926-931.
  • 3BONORA E, KIEEHL S, OBERHOLLENZEER F, et al. Impaired glucose tolerance, type 2 diabetes mellitus and carotid arteriosclerosis , prospective results from the Bruncek Study [ J ]. Diabetologia,2000,43 ( 2 ) : 156-164.
  • 4赵林双,陈玉石,向光大,候洁,乐岭,蒋文,曹红燕,徐琳,郑敏.武汉地区中老年人糖耐量受损和2型糖尿病患病率调查[J].中华糖尿病杂志(1006-6187),2005,13(6):448-449. 被引量:32
  • 5陈开宁,苏哲坦,高勇义.餐后血糖与血管并发症[J].心血管病学进展,2007,28(5):789-792. 被引量:5
  • 6罗莉,吴可贵.高血压合并糖尿病患者颈动脉内膜-中层厚度的观察[J].高血压杂志,2004,12(6):512-514. 被引量:11
  • 7HANEFELD M,CHIASSON J L ,KOEHLEV C , et al. Acarbose slows progression of intimamcdia thickness of the carotid arteries in subjects with impaired glucose tolerance[ J]. Stroke,2004,35 (5) : 1073-1078.
  • 8CHIASSON J L,JOSSE R G, GOMIS R, et al. Acarbose treatment on the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trail[J]. JAMA,2003,290(4):486-494.
  • 9OGAWA S,TAKEUCHI K, ITO S. Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes [ J ]. Diabetes Obes Metab,2004,6 ( 5 ) :384-390.
  • 10CHIASSON J L,JOSSE R G,GOMIS R,et al. Acarbose for prevention of type 2 diabetes mellitus : the STOP-NIDDM randomized trial[ J] . Lancet , 2002 , 359 (9323) :2072-2077.

二级参考文献39

  • 1Assmann G,Schulte H. The prospective cardiovascular munster(PROCAM) study: preralence of hyperlipidemia in patients with hypertension and diadetes mellitus and relationship to coronary heart disease[J].Am Heart J,1998,116:1713.
  • 2Lakka TA, Lakka HM, Salonen R. Abdominal obesity is associated with accelerated progression of carotid atherosclerosis in men[J].Atheroslerosis,2001,154:479.
  • 3Magyar MT, Paragh G, Katona E, et al. Serum cholesterols have a more important role than triglycerides in determining intima-media thickness of the common carotid artery in subjects younger than 55 years of age[J].J ultrasound Med,2004,23:1161-1169
  • 4Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial[J].Lancet,2004,364:685-696.
  • 5Haffner SM, Agostino RD Jr, Saad MF, et al. carotid artery atherosclerosis in type 2 diabetic and nondiabetic subjects with and without symptomatic coronary artery disease (The Insulin Resistance Atheroslerosis Study)[J].Am J Cardiol,2000,85:1395.
  • 6DeFronzo RA, Bonadonna RC, Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care, 1992, 15: 318-368.
  • 7Rosmond R, Chagnon YC, Holm G, et al. Hypertension in obesity and the leptin receptor gene locus. J Clin Endocrinol Metab, 2000, 85: 3126-3131.
  • 8Carpentier A, Mittelman SD, Bergman RN, et al. Prolonged elevation of plasma free fatty acids impairs pancreatic beta-cell function in obese nondiabetic humans but not in individuals with type 2 diabetes. Diabetes, 2000, 49: 399-408.
  • 9Belfiore F, Iannello S, Camuto M, et al. Insulin sensitivity of blood glucose versus insulin sensitivity of blood free fatty acids in normal, obese, and obese-diabetic subjects. Metabolism, 2001, 50: 573-582.
  • 10Fukushima M, Taniguchi A, Sakai M, et al. Homeostasis model assessment as a clinical index of insulin resistance. Comparison with the minimal model analysis. Diabetes Care, 1999, 22: 1911-1912.

共引文献60

同被引文献3

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部